News :: Kazia Therapeutics (KZIA)

Nov 4, 2021 8:00 am EDT Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

Oct 6, 2021 10:00 am EDT Kazia Therapeutics to Present at LD Micro Main Event

Sep 10, 2021 12:30 pm EDT Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

Jul 21, 2021 10:00 am EDT Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

Jun 30, 2021 10:00 am EDT Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

Jun 15, 2021 10:00 am EDT Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

Jun 7, 2021 8:00 am EDT Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Jun 3, 2021 7:00 am EDT Kazia Therapeutics to Present at LD Micro Invitational XI

Apr 19, 2021 6:11 am EDT Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

Mar 29, 2021 5:49 am EDT Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company